Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models

Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models

Abstract Regorafenib is an orally administered inhibitor of protein kinases involved in tumor angiogenesis, oncogenesis, and maintenance of the tumor microenvironment. Phase III studies showed that regorafenib has efficacy in patients with advanced gastrointestinal stromal tumors or treatment‐refrac...

Full description

Bibliographic Details
Main Authors:	Dieter Zopf, Iduna Fichtner, Ajay Bhargava, Wolfram Steinke, Karl‐Heinz Thierauch, Konstanze Diefenbach, Scott Wilhelm, Frank‐Thorsten Hafner, Michael Gerisch
Format:	Article
Language:	English
Published:	Wiley 2016-11-01
Series:	Cancer Medicine
Subjects:	Antitumor activity metabolite multikinase inhibitor pharmacology regorafenib
Online Access:	https://doi.org/10.1002/cam4.883

Similar Items

Lupus-Like Glomerulonephritis Associated With Regorafenib, a Multikinase Inhibitor
by: Anna Strasma, et al.
Published: (2021-03-01)

Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a “me too” drug?
by: Goel G
Published: (2018-03-01)

Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study
by: Thomas Brodowicz, et al.
Published: (2020-12-01)

Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications
by: Nicola Personeni, et al.
Published: (2018-06-01)

Impact of preexisting proteinuria on the development of regorafenib-induced problematic proteinuria in real-world metastatic colorectal cancer treatment
by: Yoshitaka Saito, et al.
Published: (2024-03-01)

The use of regorafenib in colorectal cancer
by: Marina I Sekacheva, et al.
Published: (2019-06-01)

Osteosarcoma of rib treated with regorafenib: a case report
by: Cemre Uçaryılmaz, et al.
Published: (2021-03-01)

Effect of Synchronous Versus Sequential Regimens on the Pharmacokinetics and Biodistribution of Regorafenib with Irradiation
by: Tung-Hu Tsai, et al.
Published: (2021-03-01)

Regorafenib in glioblastoma recurrence: A case report
by: Beatrice Detti, et al.
Published: (2021-01-01)

Effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice
by: Sylvia Grünewald, et al.
Published: (2023-04-01)

Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study
by: Anant Ramaswamy, et al.
Published: (2019-01-01)

The use of regorafenib in patients with disseminated gastrointestinal stromal tumours. A review of the literature. A clinical case
by: D. A. Filonenko, et al.
Published: (2018-07-01)

Using of multi-kinase inhibitor regorafenib for metastatic colorectal cancer
by: O I Kit, et al.
Published: (2017-06-01)

The role of regorafenib in the treatment of metastatic colorectal cancer
by: A A Tryakin
Published: (2016-06-01)

Prolonged Response to Regorafenib in a Patient with Iodine Refractory Thyroid Cancer
by: Selina K. Wong, et al.
Published: (2019-10-01)

Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan
by: Kun-Huei Yeh, et al.
Published: (2021-11-01)

Regorafenib: from clinical research to clinical practice
by: M Yu Fedyanin, et al.
Published: (2017-09-01)

Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
by: Cheol-Hyung Lee, et al.
Published: (2020-07-01)

Case Report: Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule
by: Maria Susanna Grimaudo, et al.
Published: (2023-05-01)

Regorafenib in Glioblastoma Recurrence: How to Deal With MR Imaging Treatments Changes
by: Simona Gaudino, et al.
Published: (2022-02-01)

Efficacy and safety of regorafenib versus dinutuximab with chemotherapy in Chinese children with neuroblastoma
by: Kun Dong, et al.
Published: (2019-02-01)

Synergistic antitumor activity of regorafenib and rosuvastatin in colorectal cancer
by: Tao Yuan, et al.
Published: (2023-04-01)

A Practical and Efficient Method for the Synthesis of Sorafenib and Regorafenib
by: Ramteke Prachi, et al.
Published: (2023-09-01)

Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels
by: Po‐Yao Hsu, et al.
Published: (2022-01-01)

Real-Life Experience of Regorafenib in Patients With Advanced Hepatocellular Carcinoma
by: Jing-Yu Hou, et al.
Published: (2022-06-01)

A Promising Role of TGF-β Pathway in Response to Regorafenib in Metastatic Colorectal Cancer: A Case Report
by: Simona De Summa, et al.
Published: (2021-11-01)

Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug Resistance
by: Pashalina Kehagias, et al.
Published: (2022-11-01)

Regorafenib monotherapy or combined with an immune-checkpoint inhibitor as later-line treatment for metastatic colorectal cancer: a multicenter, real-world retrospective study in China
by: Wang Qu, et al.
Published: (2024-01-01)

Discovery of SIPI6473, a New, Potent, and Orally Bioavailable Multikinase Inhibitor for the Treatment of Non-small Cell Lung Cancer
by: Xiu Gu, et al.
Published: (2021-03-01)

Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer
by: Kawakami K, et al.
Published: (2019-10-01)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
by: Yuan-Hung Kuo, et al.
Published: (2021-05-01)

Regorafenib application in patients with metastatic colorectal cancer in actual clinical practice
by: M I Sekacheva, et al.
Published: (2016-09-01)

Effect of starting dose of regorafenib on overall survival of patients with metastatic colorectal cancer: a systematic review and meta-analysis
by: Mikhail Yu Fedyanin, et al.
Published: (2019-09-01)

Fatal Acute Liver Failure as a Consequence of Regorafenib Treatment in a Metastatic Colon Cancer
by: Dominique Béchade, et al.
Published: (2017-08-01)

Regorafenib in Recurrent Glioblastoma Patients: A Large and Monocentric Real-Life Study
by: Giuseppe Lombardi, et al.
Published: (2021-09-01)

Cross-Resistance of Acquired Radioresistant Colorectal Cancer Cell Line to gefitinib and regorafenib
by: Saeid Afshar, et al.
Published: (2020-01-01)

Long‐term survival of an advanced colorectal cancer patient treated with Regorafenib: Case report and literature review
by: Oronzo Brunetti, et al.
Published: (2019-12-01)

Regorafenib Suppresses Migration of and Induces Cell Cycle Arrest and Apoptosis in MCF-7 Cells
by: Dawei Wang, et al.
Published: (2021-10-01)

Regorafenib beyond the Second Line in Relapsed Glioblastoma: A Case Report and Literature Review
by: Mario Pirozzi, et al.
Published: (2022-06-01)

Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study
by: Yue Han, et al.
Published: (2021-10-01)